Evidence of the Benefit of Immunotherapy
Since 2020, Pembrolizumab has been approved by NICE as an option for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more. Now, evidence has emerged from a large international clinical trial about the effectiveness of this immunotherapy when […]